TITLE

Pneumocystis carinii pneumonia

PUB. DATE
June 1997
SOURCE
MMWR: Morbidity & Mortality Weekly Report;6/27/1997 Supplement RR-12, Vol. 46, p4
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Provides information on the disease pneumocystis carinii pneumonia. Recommendation made by authorities relating to the prevention of exposure to disease; Precautions that should be considered by adolescents, adults and pregnant women.
ACCESSION #
9708316374

 

Related Articles

  • 1995 revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children...  // MMWR: Morbidity & Mortality Weekly Report;4/28/95 Supplement RR-4, Vol. 44 Issue 16, p1 

    Presents the revised prevention guidelines for prophylaxis against Pneumocystis carinii pneumonia (PCP) for children infected with or perinatally exposed to human immunodeficiency virus (HIV). Recommendations including the prompt diagnosis of children born to HIV-infected women; Timing and...

  • Prophylactic Treatment of P. Carinii Pneumonia. Walling, Anne D. // American Family Physician;2/15/2000, Vol. 61 Issue 4, p1145 

    Highlights the study `Efficacy of Azithromycin in Prevention of Pneumocystis carinii pneumonia: A Randomised Trial,' by M.W. Dunne and colleagues published in the September 11, 1999 issue of `Lancet.'

  • Penatmidine prevented pneumocystosis among pediatric HSCT patients.  // Infectious Disease News;May2013, Vol. 26 Issue 5, p28 

    The article discusses research which revealed that intravenous pentamidine is safe and effective for the prevention of Pneumocystis carinii pneumonia in pediatric hematopoietic stem cell transplantation patients, published in a 2013 issue of the "Pediatric Infectious Diseases Journal."

  • Clinic HIV-focused features and prevention of Pneumocystis carinii pneumonia. Turner, Barbara J.; Md; Markson, Leona; Cocroft, James; Cosler, Leon; Hauck, Walter W.; Turner; Turner, B J; Markson, L; Cocroft, J; Cosler, L; Hauck, W W // JGIM: Journal of General Internal Medicine;Jan1998, Vol. 13 Issue 1, p16 

    Objective: To examine the association of clinic HIV-focused features and advanced HIV care experience with Pneumocystis carinii pneumonia (PCP) prophylaxis and development of PCP as the initial AIDS diagnosis.Design: Nonconcurrent prospective study.Setting:...

  • PNEUMOCYSTIS CARINII PNEUMONIA CHEMOPROPHYLAXIS IN HIV+ PATIENTS IN GLASGOW: AN AUDIT. Wardle, D.M.; Kennedy, D. // Sexually Transmitted Infections;Jun2003 Supplement 1, Vol. 79, pA22 

    Introduction: We audited chemoprophylactic use against Pneumocystis carinii pneumonia (PCP) in our HIV+ patients using US Public Health Service and Infectious Diseases Society of America USPHS/IDSA guidelines as a standard in the absence of definitive UK guidelines. Methods: Criteria for...

  • NO DIFFERENCE WITH ATOVAQUONE.  // AIDS Patient Care & STDs;Nov99, Vol. 13 Issue 11, p681 

    Reports the efficacy of atovaquone suspension in preventing pneumocystis carinii pneumonia in HIV-infected patients. Comparison to aerosolized pentamidine; Treatment in patients intolerant to trimethoprim/sulfonamides; Impact on incidence and mortality.

  • Diagnostic and Therapeutic Technology Assessment (DATTA).  // JAMA: Journal of the American Medical Association;5/9/90, Vol. 263 Issue 18, p2510 

    Discusses the use of aerosolized pentamidine in preventing recurrent Pneumocystis carnii infection in HIV-positive patients. Mechanism of action of the drug; Effectiveness and safety of the drug; Method of delivery of aerosolized pentamidine.

  • PCP prophylaxis with use of corticosteroids by neurologists. Kelly, Dearbhla M.; Cronin, Simon // Practical Neurology (BMJ Publishing Group);Apr2014, Vol. 14 Issue 2, p74 

    Pneumocystis jirovecii pneumonia (PCP) is increasingly reported in patients without HIV. Corticosteroids are a major risk factor, with up to 90% of patients receiving corticosteroid treatment prior to the development of PCP. In view of this, many specialties now prescribe PCP prophylaxis to...

  • Point prevalence of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma according to the number of cycles of R-CHOP chemotherapy. Kim, Tark; Choi, Sang-Ho; Kim, Sung-Han; Jeong, Jin-Yong; Woo, Jun; Kim, Yang; Sung, Heungsup; Kim, Mi-Na; Yoon, Dok; Suh, Cheolwon; Lee, Sang-Oh // Annals of Hematology;Feb2013, Vol. 92 Issue 2, p231 

    R-CHOP chemotherapy composed of rituximab, cyclophosphamide, adriamycin, vincristine, and prednisolone which might increase the risk of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma. We estimated the point prevalence of Pneumocystis pneumonia in non-Hodgkin lymphoma patients...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics